Welcome to our dedicated page for Atara Biotherapeutics news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics stock.
Atara Biotherapeutics, Inc (Symbol: ATRA) is a pioneering company in the healthcare sector, specializing in the development of transformative therapies for patients combating serious diseases, including cancer, kidney disease, and autoimmune disorders. Founded in August 2012, Atara Biotherapeutics is driven by a mission to provide better treatment options for patients, inspired by Atara Ciechanover, who tragically passed away from cancer in 2012.
The company's research is founded on groundbreaking discoveries related to activin, myostatin, and other growth factors that can alter disease progression. Atara's innovative approach has led to the development of several promising product candidates:
- Pinta 745
- STM 434
- ATA 842
Moreover, Atara Biotherapeutics is collaborating with the prestigious Memorial Sloan Kettering Cancer Center (MSK) to develop three cutting-edge T-cell product candidates:
- Epstein-Barr Virus (EBV)-targeted Cytotoxic T Lymphocytes (CTLs)
- Cytomegalovirus (CMV)-targeted CTLs
- Wilms Tumor 1 (WT1)-targeted CTLs
These T-cell therapies are designed to tackle the underlying mechanisms of various diseases, offering hope for conditions that are currently challenging to treat.
Atara's product pipeline also includes Tab-cel, ATA188, and ATA3219 (CAR T platform). Each of these candidates targets specific mechanisms of disease, aiming to provide effective and innovative treatment solutions.
The company operates within the US healthcare sector, managing its business as a single operating and reportable segment focused on therapeutic development. Atara Biotherapeutics continues to make strides in its mission, marked by recent achievements and partnerships that underscore its commitment to improving patient outcomes.
Stay updated with the latest news and developments from Atara Biotherapeutics to gain insights into their ongoing projects and performance in the stock market.
Atara Biotherapeutics (Nasdaq: ATRA) has joined the Rare Disease Company Coalition, focusing on developing treatments for rare diseases like EBV-driven post-transplant lymphoproliferative disease. This alliance of life sciences companies aims to inform policymakers about the unique challenges in rare disease therapies and advocate for supportive policies to enhance innovation and access to treatments. Atara is committed to addressing the urgent needs of patients with rare blood cancers and is actively engaging with industry peers to advance effective healthcare initiatives.
Atara Biotherapeutics (Nasdaq: ATRA) recently presented long-term overall survival (OS) data for its therapy, tabelecleucel (tab-cel), aimed at patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD). Presented at the American Transplant Congress 2021, the analysis from three clinical studies shows a 1-year and 2-year OS rate of 100% and 87.5%, respectively, in certain patient groups. Tab-cel was well tolerated, with no significant safety issues reported, addressing a critical need in treating this high-mortality condition.
Atara Biotherapeutics (Nasdaq: ATRA) announced the granting of 140,861 restricted stock units and stock options for 124,966 shares to newly hired employees, approved by the Compensation Committee. The awards are part of the 2018 Inducement Plan, with vesting periods spanning four years. The stock options have a ten-year term and an exercise price of $13.97, equal to the closing price on June 1, 2021. This information is provided in compliance with Nasdaq Listing Rule 5635(c)(4), highlighting Atara's commitment to attracting talent as it advances its T-cell immunotherapy platform.
Atara Biotherapeutics (Nasdaq: ATRA) has granted inducement awards to Cokey Nguyen, the new Senior VP and Chief Scientific Officer. The awards include 115,440 restricted stock units and stock options for 174,249 shares, part of the 2018 Inducement Plan, dated May 10, 2021. The restricted stock units will vest over four years, while stock options will have a ten-year term at an exercise price of $13.24 per share. This move adheres to Nasdaq Listing Rule 5635(c)(4), aimed at attracting key talent for the company's ongoing development in T-cell immunotherapy.
Atara Biotherapeutics (Nasdaq: ATRA) announced participation in the Cowen Virtual Oncology Innovation Summit on May 20, 2021, featuring CEO Pascal Touchon and CMO AJ Joshi. The discussion will focus on Atara's innovative T-cell immunotherapy platform aimed at treating serious conditions such as solid tumors and autoimmune diseases. A live webcast will be available on Atara's website, with an archived replay accessible for 30 days post-event. Atara is leading in T-cell immunotherapy development with a robust pipeline, including treatments for Epstein-Barr virus-driven diseases.
Atara Biotherapeutics (Nasdaq: ATRA) has appointed Dr. Cokey Nguyen as Chief Scientific Officer, enhancing its focus on T-cell immunotherapy. Dr. Nguyen brings extensive experience from leadership roles at Fate Therapeutics and Pfizer, specializing in oncology and cell therapy. His expertise aims to accelerate Atara's pipeline, which includes therapies for EBV-related diseases and multiple sclerosis. Atara's ongoing commitment to innovation is highlighted as they expand their allogeneic EBV T-cell platform, with a goal of providing transformative treatments for patients with unmet medical needs.
Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 229,931 restricted stock units and 206,167 stock options to newly hired employees, approved by its Compensation Committee under the 2018 Inducement Plan. The grants, dated May 3, 2021, aim to attract talent essential for advancing Atara's allogeneic EBV T-cell platform targeting serious diseases. Restricted stock units vest over four years, while stock options have a ten-year term with an exercise price of $14.05 per share. This decision complies with Nasdaq Listing Rule 5635(c)(4).
Atara Biotherapeutics reported financial results for Q1 2021, highlighting progress in its T-cell immunotherapy programs. The company is advancing the tab-cel® BLA and MAA filings, with ongoing discussions with the FDA and EMA. In Q1 2021, cash reserves totaled $435.2 million, with license revenue of $3.6 million. Net losses were $78.3 million, or $0.86 per share. Increased R&D expenses were noted, driven by higher headcount and program costs. Atara anticipates significant milestones in 2021, including interim data from the ATA188 study and presentation of CAR T data.
Atara Biotherapeutics (Nasdaq: ATRA) will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 4:30 p.m. EDT for analysts and investors to discuss the results and receive a corporate update. Participants can join the conference call via phone or through a live audio webcast available on Atara's website. The company is focused on developing T-cell immunotherapies for serious diseases, including solid tumors and hematologic cancers, utilizing its EBV T-cell platform.
Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 52,019 restricted stock units and stock options for 82,342 shares to newly hired employees. This decision, approved by the Compensation Committee, is part of Atara's 2018 Inducement Plan. The restricted stock units vest over four years, while the stock options have a ten-year term with an exercise price of $14.91 per share, based on the closing price on April 1, 2021. This move aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for new hires.
FAQ
What is the current stock price of Atara Biotherapeutics (ATRA)?
What is the market cap of Atara Biotherapeutics (ATRA)?
What does Atara Biotherapeutics, Inc specialize in?
When was Atara Biotherapeutics founded?
Who is Atara Ciechanover?
What are some of Atara's key product candidates?
With which institution is Atara Biotherapeutics collaborating?
What types of T-cell therapies is Atara developing?
What is the mission of Atara Biotherapeutics?
Where does Atara Biotherapeutics operate?
What are activin and myostatin in the context of Atara's research?
How does Atara manage its business operations?
